BioPharmSignal logoBioPharmSignal

Biotech News

Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria

Disc Medicine (IRON)Disc MedicineFDA / regulatory

Aligned with the FDA that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response and could potentially support a traditional approval On track for expected CRL response submission by end of 2026 WATERTOWN, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc.

Related news

IRONDisc Medicine2026-02-13 20:04 EST

Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP

IRONDisc Medicine2026-01-12 13:30 EST

Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026

APTOAptose Biosciences, Inc.2026-03-31 21:22 EST

Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights

RCKTRocket Pharmaceuticals2026-03-27 11:00 EST

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

KPTIKaryopharm Therapeutics2026-07-30 20:06 EST

Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway

RCKTRocket Pharmaceuticals2025-10-14 11:00 EST

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

APTOAptose Biosciences, Inc.2025-11-03 14:00 EST

Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting

APVOAptevo Therapeutics2025-12-09 13:05 EST

Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025

View all latest news

Disc Medicine

Hematology Drug Development Disc Medicine develops therapies for serious hematologic diseases by targeting pathways involved in heme biosynthesis and iron regulation. Its portfolio addresses both rare red-blood-cell disorders and anemia associated with chronic disease. Bitopertin in EPP Bitopertin is being evaluated in the Phase 3 APOLLO...

Recent company news

IRONDisc Medicine2026-07-30 12:30 EST

Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update

IRONDisc Medicine2026-06-12 12:30 EST

Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting

IRONDisc Medicine2026-06-09 12:30 EST

Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria

IRONDisc Medicine2026-06-02 12:00 EST

Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

IRONDisc Medicine2026-06-01 12:30 EST

Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients

Stock data

Close
77.44 USD
Market cap
2.6B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States